SCHEMBL4151784

SCHEMBL4151784

CNCC(F)(F)CNC(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
GAA P10253 1/20 0.41
EPHX1 P07099 1/20 0.40
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
LMNA P02545 2/20 0.37
POLB P06746 1/20 0.37
APLNR P35414 1/20 0.37
CA1 P00915 4/20 0.36
CA2 P00918 3/20 0.36
CA12 O43570 3/20 0.36
CA9 Q16790 2/20 0.36
CACNA1H O95180 1/20 0.36
CACNA1B Q00975 1/20 0.36
CACNA1C Q13936 1/20 0.36
CA7 P43166 2/20 0.35
ALDH1A1 P00352 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13449471 0.83 TDP1 (0.49) TDP1MEN1KMT2AGAAEPHX1
SCHEMBL14744344 0.83 TDP1 (0.44) TDP1MEN1KMT2AGAAEPHX1
SCHEMBL22950318 0.81 TDP1 (0.43) TDP1MEN1KMT2AGAAEPHX1
SCHEMBL1233767 0.81 TDP1 (0.43) TDP1MEN1KMT2AGAAEPHX1
SCHEMBL2562318 0.81 TDP1 (0.46) TDP1MEN1KMT2AGAAEPHX1
SCHEMBL24875278 0.81 MEN1 (0.41) TDP1MEN1KMT2AGAAEPHX1
SCHEMBL26498818 0.81 MAOA (0.53) TDP1MEN1KMT2AGAAEPHX1
SCHEMBL4202727 0.80 TDP1 (0.48) TDP1MEN1KMT2AGAAEPHX1
SCHEMBL12698678 0.80 TDP1 (0.48) TDP1MEN1KMT2AGAAEPHX1
SCHEMBL843323 0.80 TDP1 (0.48) TDP1MEN1KMT2AGAAEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9023860-B2 Pro-drugs for controlled release of biologically active compounds SIGNATURE THERAPEUTICS, INC. (US) 2015-05-05 US disclosed
US-9023860-B2 Pro-drugs for controlled release of biologically active compounds SIGNATURE THERAPEUTICS, INC. (US) 2015-05-05 US disclosed
US-20090137618-A1 PRO-DRUGS FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS 3I, LP 2009-05-28 US disclosed
US-20090137618-A1 PRO-DRUGS FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS 3I, LP 2009-05-28 US disclosed
US-20090137618-A1 PRO-DRUGS FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS 3I, LP 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137618-A1 PRO-DRUGS FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS CRH, FURIN, PEPD TDP1 2767/4885MEN1 335/4885KMT2A 4268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.